Iqbal Madiha, Akhter Naheed
Obstetrics and Gynaecology, Hayatabad Medical Complex Peshawar, Peshawar, PAK.
Obstetrics and Gynaecology, Khyber Teaching Hospital, Peshawar, PAK.
Cureus. 2024 Dec 24;16(12):e76336. doi: 10.7759/cureus.76336. eCollection 2024 Dec.
Background Hysteroscopy, a minimally invasive procedure for diagnosing and treating intrauterine pathologies, can be challenging due to inadequate cervical dilation, leading to procedural difficulties and patient discomfort. Misoprostol, a synthetic prostaglandin E1 analog, is increasingly used for cervical ripening to ease hysteroscopic procedures. Objective To evaluate the efficacy and safety of misoprostol for cervical ripening prior to hysteroscopy. Material and methods This prospective study included 539 women who presented to the Gynecology OPD for elective hysteroscopy. Participants were randomly assigned to either Group A (n=300), who received 400 µg misoprostol vaginally at night before hysteroscopy, or Group B (n=239), who had a placebo. The outcomes assessed were cervical dilation, procedural time, patient-reported pain during hysteroscopy, and placement of a copper IUD on post-insertion day 1 as defined by the visual analog score (VAS), incidence of cervical lacerations, or adverse side effects. Results Group A had significantly higher rates of achieving greater cervical dilation compared to Group B. Specifically, 50% of patients in Group A achieved a dilation of 7-8 mm, and 15% achieved dilation greater than 8 mm, whereas only 10% and 5% of patients in Group B achieved these levels of dilation, respectively. The need for additional mechanical dilation was lower in Group A (10% vs. 55%). Procedural times were shorter in Group A, with 75% of procedures taking 10 minutes or less compared to 30% in Group B. Patient-reported pain was also lower in Group A. Conclusion Misoprostol improves cervical ripening before hysteroscopy, reducing the need for mechanical dilation, shortening operation time, and lowering pain levels. Despite moderate side effects, it remains a key preoperative cervical preparation due to its procedural and patient comfort benefits.
宫腔镜检查是一种用于诊断和治疗子宫内病变的微创手术,但由于宫颈扩张不足,可能具有挑战性,会导致手术困难和患者不适。米索前列醇是一种合成的前列腺素E1类似物,越来越多地用于宫颈成熟,以简化宫腔镜手术。目的:评估米索前列醇在宫腔镜检查前用于宫颈成熟的有效性和安全性。材料和方法:这项前瞻性研究纳入了539名到妇科门诊进行择期宫腔镜检查的女性。参与者被随机分为A组(n=300),在宫腔镜检查前一晚经阴道给予400μg米索前列醇,或B组(n=239),给予安慰剂。评估的结果包括宫颈扩张、手术时间、患者报告的宫腔镜检查期间的疼痛,以及根据视觉模拟评分(VAS)定义的术后第1天放置铜宫内节育器的情况、宫颈撕裂的发生率或不良副作用。结果:与B组相比,A组实现更大宫颈扩张的比例显著更高。具体而言,A组50%的患者宫颈扩张达到7-8mm,15%的患者宫颈扩张大于8mm,而B组分别只有10%和5%的患者达到这些扩张水平。A组额外进行机械扩张的需求较低(10%对55%)。A组的手术时间更短,75%的手术时间为10分钟或更短,而B组为30%。A组患者报告的疼痛也更低。结论:米索前列醇可改善宫腔镜检查前的宫颈成熟,减少机械扩张的需求,缩短手术时间,并降低疼痛水平。尽管有中度副作用,但由于其在手术操作和患者舒适度方面的益处,它仍然是关键的术前宫颈准备方法。